ICH Q11 and Peptide Manufacturing: Compliance Updates and Interpretation Guidance for 2026

ICH Q11, the harmonized guideline on development and manufacture of drug substances, provides the regulatory framework for process design, characterization, and control of pharmaceutical drug substances, including synthetic peptides. Since its initial implementation, manufacturers and regulators have worked through the interpretation challenges that arise when applying Q11's principles to peptide-specific manufacturing scenarios. In 2026, the accumulated guidance from FDA, EMA, and the ICH Implementation Working Group provides clearer compliance expectations for peptide API manufacturers than existed even three years ago.

ICH Q11 Scope and Applicability to Peptides

ICH Q11 explicitly covers "drug substances that are small molecules or proteins/polypeptides manufactured by chemical synthesis, semi-synthesis, or fermentation." Synthetic peptides fall within the small molecule / chemical synthesis scope for peptides below approximately 40 amino acids without complex post-translational modifications, while longer peptides and those with more complex structures may be evaluated under the biological framework.

The practical implication is that the majority of peptide drugs in current development, GLP-1 analogs, LHRH agonists and antagonists, somatostatin analogs, antimicrobial peptides, are regulated as synthetic small molecules under ICH Q11 rather than as biologics under ICH Q6B. This classification affects not only the regulatory framework for the drug substance but also the manufacturing GMP requirements, the analytical methods expected for control, and the specification approach.

Key ICH Q11 Concepts Applied to Peptide Manufacturing

Critical Quality Attributes (CQAs). ICH Q11 requires manufacturers to identify and justify the CQAs for the drug substance, the properties that must be within defined limits to ensure the desired product quality. For synthetic peptides, the standard CQA set includes:

• Identity (amino acid sequence, confirmed by mass spectrometry or amino acid analysis)
• Purity (by HPLC, with impurity identification and quantification)
• Peptide content (potency on a weight/weight basis, accounting for water content and counterion)
• Water content (by Karl Fischer titration for lyophilized peptides)
• Counterion content (TFA, acetate, or other anions from HPLC purification)
• Microbial limits (for sterile injectable manufacturing)
• Residual solvents (ICH Q3C compliant)

For modified peptides, those with fatty acid conjugates, PEGylation, or other structural modifications, additional CQAs specific to the modification are required: degree of conjugation, distribution of conjugation sites, modification characterization by MS.

Control Strategy. The Q11 control strategy concept requires manufacturers to define, for each CQA, the combination of in-process controls, material controls, finished product testing, and process design that ensures the CQA is consistently achieved. For peptide manufacturers, this typically involves:

• Amino acid coupling yield monitoring (ninhydrin or TNBS tests) as in-process controls during SPPS to detect coupling failures that would generate deletion sequences
• Deprotection completeness verification before proceeding to next synthesis steps
• Intermediate peptide purity verification at key synthesis stages before conjugation or cyclization steps
• Final product purity by HPLC as a release specification, with the method validated to resolve the target peptide from its process impurities and degradation products

Process Analytical Technology (PAT). ICH Q11 encourages the use of PAT tools for real-time monitoring and control. In peptide manufacturing, the most mature PAT applications are:

• Online HPLC or UV monitoring of eluent fractions during preparative chromatographic purification to enable real-time fraction selection
• Near-infrared spectroscopy for solvent content monitoring during lyophilization
• Inline UV monitoring of synthesis reactor output to detect coupling failures

Adoption of PAT in peptide manufacturing has been slower than in small-molecule API manufacturing, partly due to the complexity of the analytical methods required and partly due to the batch sizes (often relatively small for clinical-phase peptides) that complicate the cost justification. However, CDMOs scaling up for commercial GLP-1 production are increasingly investing in PAT infrastructure as part of continuous manufacturing initiatives.

The "Starting Material" Definition Challenge

One of the most practically important and contentious ICH Q11 questions for peptide manufacturers is the definition of the drug substance starting material, the point in the synthesis at which GMP controls must begin. For small-molecule APIs, starting material definition involves establishing a stage of synthesis at which the starting material has a suitable chemical structure and commercially available specifications.

For peptide APIs manufactured by SPPS, the analogous question is: at what stage does GMP apply, the individual protected amino acid building blocks, the resin-loaded first amino acid, the partially assembled peptide chain, or the crude peptide after cleavage?

Current FDA and EMA practice:

• Protected amino acid building blocks purchased from commodity chemical suppliers are typically treated as non-GMP starting materials, with appropriate qualification of the supplier's analytical certificates
• The resin loading and first amino acid coupling is typically the starting material for GMP purposes when using standard amino acid building blocks, i.e., the entire SPPS process is conducted under GMP
• For longer or more complex peptides where key building blocks are unique modified amino acids or unusual protecting group strategies, the synthesis of these key building blocks may itself need to be conducted under GMP

Regulatory agencies have become more prescriptive about starting material definitions following several cases where API manufacturers defined starting materials so early in the synthesis that GMP control over the key synthesis steps was minimal. The trend is toward earlier definition of GMP starting material scope, and manufacturers should expect scrutiny of starting material justifications during pre-approval inspections.

Process Validation Requirements for Peptide APIs

For peptide APIs in commercial manufacturing, the process validation expectations under ICH Q11 require demonstration that the manufacturing process consistently produces drug substance meeting its specifications, typically through three validation batches at commercial scale, demonstrating batch-to-batch consistency in the critical process parameters and CQAs.

Key validation challenges specific to peptide SPPS manufacturing include:

Resin performance variability. Solid-phase resins can exhibit lot-to-lot variation in loading capacity, swelling properties, and flow characteristics that affects synthesis performance. Validation of resin specifications and suppliers is required, and resin qualification testing should be included in the raw material control program.

Coupling reagent and solvent quality. The quality of coupling reagents (HBTU, HATU, DIC) and solvents (DMF, NMP, DCM) directly affects coupling efficiency and impurity generation. These materials must be characterized, qualified, and controlled to maintain process consistency.

Preparative HPLC reproducibility. Purification by preparative reversed-phase HPLC is the primary impurity removal step for most synthetic peptides. Column performance (theoretical plates, peak symmetry) and mobile phase composition must be monitored and controlled across the validation campaign and into commercial manufacturing.

Lyophilization cycle development. Lyophilization cycle parameters affect the physical form (amorphous vs. crystalline), residual moisture, and reconstitution properties of the final peptide API. Lyophilization cycle validation requires demonstration of acceptable product properties across the load variability and equipment parameters expected in commercial operations.

Implications for Small and Mid-Size Peptide Manufacturers

For smaller peptide manufacturers, boutique CDMOs, university spinouts entering commercial development, and specialty pharma companies with in-house peptide synthesis, the ICH Q11 compliance requirements for commercial-stage manufacturing represent a significant organizational investment. The key capability requirements include:

• A robust quality management system with formal document control, deviation management, and CAPA procedures
• Validated analytical methods for all release and in-process testing
• A trained quality assurance function with peptide-specific technical expertise
• Process validation executed by a multidisciplinary team spanning chemistry, analytical science, and quality

Companies that have developed these capabilities for clinical-phase manufacturing will need to extend and formalize them for commercial-stage readiness. The gap between Phase 2 GMP operations and Phase 3 / commercial-stage compliance is substantial, and companies should begin planning the organizational and infrastructure investments for commercial readiness no later than Phase 2 initiation.

Regulatory agencies routinely flag ICH Q11 compliance gaps during pre-NDA meetings, and addressing these gaps reactively, under submission timelines, is more costly and disruptive than proactive investment in quality systems infrastructure during development.

The ICH Q11 framework, applied consistently and with peptide-specific technical depth, provides a sound basis for manufacturing control that protects product quality and patient safety. Companies that internalize its principles, rather than treating compliance as a documentation exercise, build manufacturing operations that perform better commercially and experience fewer post-approval regulatory challenges.